Real World Experience with Tofacitinib in IBD at a Tertiary Center

BACKGROUND AND AIMS: Many inflammatory bowel disease (IBD) patients do not respond to medical therapy. Tofacitinib is a first in class, partially selective inhibitor of Janus kinase, recently approved for treating patients with ulcerative colitis (UC). We describe our experience with the use of tofa...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Dig Dis Sci
Autori principali: Weisshof, Roni, Golan, Maya A., Sossenheimer, Philip H., Jurdi, Katia El, Ollech, Jacob E., Pekow, Joel, Cohen, Russel D., Sakuraba, Atsushi, Dalal, Sushila, Rubin, David T.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6935176/
https://ncbi.nlm.nih.gov/pubmed/30734234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10620-019-05492-y
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi